Cartel agreements are illegal and unethical practices where companies in the same industry agree to coordinate their actions to control prices, limit competition, and increase their profits. These agreements often involve secret meetings, collusion, and the exchange of sensitive information.

An example of a cartel agreement occurred in the 1990s in the global market for vitamins. The cartel, known as the “Vitamin Cartel,” involved six major companies: Roche, BASF, DSM, Takeda, Eisai, and Merck. These companies controlled more than 90% of the world`s vitamin market.

The Vitamin Cartel agreed to fix prices, limit production, and allocate market shares to maximize their profits. They also agreed to coordinate their marketing strategies and prevent new players from entering the market. This collusion resulted in increased prices for vitamins, which affected consumers worldwide.

The US Department of Justice launched an investigation into the Vitamin Cartel in the late 1990s, and several companies were fined for their involvement. Roche, for example, was fined $500 million, while BASF agreed to pay $225 million. These fines were some of the largest in antitrust history.

The Vitamin Cartel case highlights the dangers of cartel agreements and their negative impact on competition and consumers. Cartels can harm consumers by limiting their choices, raising prices, and reducing the quality of products. They also stifle innovation and prevent new players from entering the market.

In conclusion, cartel agreements are illegal and unethical practices that harm competition and consumers. The Vitamin Cartel case is an example of how collusion can lead to higher prices, reduced quality, and limited choices for consumers. Companies that engage in cartel behavior can face substantial fines and damage to their reputation. It is essential for regulatory bodies to remain vigilant and enforce antitrust laws to ensure fair competition in the market.